Expression And Significant Of Interleukin-13 In Serum And Peritoneal Fluid Of Endometriosis

Background and Objective:Endometriosis(EMs) is a common gynecologic disease, with the incidence 10～15%of women in general population. The attack rate is as high as 30%in women with infertility or chronic pelvic plain. The pathogenesis of endometriosis is not distinct. Retrograde menstruation is a widely accepted mechanism that could explain the presence of endometrial cells in ectopic sites. However, it does not account for the fact that these misplaced cells survive in women with the disease and not in healthy ones. An immunological etiology has been conjectured, as demonstrated by increased concentrations of the cytokine secreted by activated macrophages, T and B cells.Cytokine, a bioactive polypeptide with low molecular weight, is synthesized and secreted by some kind of cells. Immunologic dissonance in pelvic microenvironment plays an important role in development of endometriosis. Studies have reported abnormal levels of cytokines in the peritoneal fluid of endometriosis, thus implicating these factors in the genesis and progression of the disease.Interleukin-13 was firstly discovered in 1994, which plays a role as both immunoregulator and anti-inflammation factor. Although IL-13 stands as one of the most investigated disorders of some disease else, our current understanding of its role in endometriosis remains elusive.The objective of the present study is to detect the variation of IL-13 level in serum and peritoneal fluid of endometriosis, and to investigate the role of IL-13 in the pathogenesis of EMs.Materials and methods:Expression of IL-13 was detected the IL-13 level in peritoneal fluid and serum of 32 cases with EMs (Study group, EMs group) and counterpart of 20 cases without Ems (control group) by enzyme-linked immunosorbent assay (ELISA), the variation of IL-13 level in menstrual cycle is compared between study group and control group, and the correlation is analysed not only between IL-13 level and the Revisal-American Fertility Score (R-AFS) but also between IL-13 level in serum and in peritoneal fluid. All study subjects were recruited from Women's Hospital, College of Medicine, Zhejiang University, from December.2009 to April.2010.Results:1,IL-13 level in serum with Ems (6.95±2.74 pg/ml) was significantly lower than that in control group (12.87±9.70 pg/ml)(p<0.05), as same as that in peritoneal fluid of between EMs group (3.26±1.81 pg/ml) and control group (8.49±6.65 pg/ml)(p<0.001).2,EMs group has been divided into mild(stageⅠandⅡ) and severe group(stageⅢandⅣ) according to the stage of EMs. IL-13 level in serum has not difference not only between control group(12.87±9.70 pg/ml) and mild group(7.85±2.09 pg/ml) but also between mild group(7.85±2.09 pg/ml) and severe group(6.34±3.00 pg/ml)(p>0.05). however, IL-13 level of severe group(6.34±3.00 pg/ml) was significant lower than that of control group(12.87±9.70 pg/ml) (p<0.05). IL-13 level in peritoneal fluid of severe group(2.43±1.43pg/ml) was significant lower than that in mild group(4.48±1.63 pg/ml)(P<0.005), and IL-13 level in mild group(4.48±1.63 pg/ml) was significant lower than that in control group(8.49±6.65pg/ml) (P<0.05).3,IL-13 level in peritoneal fluid of EMs group has the negative correlation with R-AFS, and of control group, IL-13 level in serum has the positive correlation with that in peritoneal fluid.4,IL-13 level has no difference in menstrual cycle.Conclusions:1,IL-13 level which is low in peritoneal fluid has negative correlation with the severity of EMS, may play an important role in the pathogenesis of EMs.2,It has been surmised that there may be no cycle-specific differences in IL-13 level of both serum and peritoneal fluid in each group.